Capstone Therapeutics (NASDAQ:CAPS) Releases Earnings Results

Capstone Therapeutics (NASDAQ:CAPS) announced its quarterly earnings data on Tuesday. The company reported ($0.35) earnings per share (EPS) for the quarter, Zacks reports.

Capstone Therapeutics Stock Performance

NASDAQ CAPS opened at $1.08 on Tuesday. The company has a debt-to-equity ratio of 0.22, a current ratio of 0.97 and a quick ratio of 0.41. The company has a market cap of $7.87 million, a P/E ratio of -1.80 and a beta of -0.83. The stock has a 50-day moving average of $1.17 and a two-hundred day moving average of $1.45. Capstone Therapeutics has a 1-year low of $0.92 and a 1-year high of $16.18.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capstone Therapeutics in a research note on Wednesday, November 5th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism.